Zoetis Inc
ZOE
Company Profile
Business description
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Contact
10 Sylvan Way
ParsippanyNJ07054
USAT: +1 973 822-7000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
13,800
Stocks News & Analysis
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
stocks
Undervalued ASX share searches for cost savings
Cost savings from recent acquisition underpin our earnings growth forecasts.
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,983.30 | 28.90 | 0.32% |
| CAC 40 | 8,085.76 | 63.07 | 0.79% |
| DAX 40 | 24,294.61 | 164.47 | 0.68% |
| Dow JONES (US) | 48,704.01 | 646.26 | 1.34% |
| FTSE 100 | 9,703.16 | 47.63 | 0.49% |
| HKSE | 25,953.80 | 423.29 | 1.66% |
| NASDAQ | 23,593.86 | 60.30 | -0.25% |
| Nikkei 225 | 50,796.59 | 647.77 | 1.29% |
| NZX 50 Index | 13,406.91 | 11.04 | 0.08% |
| S&P 500 | 6,901.00 | 14.32 | 0.21% |
| S&P/ASX 200 | 8,697.30 | 32.40 | 0.37% |
| SSE Composite Index | 3,885.27 | 11.95 | 0.31% |